Prospective Quantitative Gene Expression Analysis of Kallikrein-related Peptidase As a Diagnostic Biomarker for Childhood Acute Lymphoblastic Leukemia

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2022 Jun 7

PMID 35669967

Authors

Shwan Majid Ahmad

Basima Sadq Ahmed

Karzan Ghafur Khidhir

Heshu Sulaiman Rahman

Affiliations

Soon will be listed here.

Abstract

Background: The most common malignancy in children is acute lymphoblastic leukemia (ALL). This study aimed to explore mRNA expression as a potential diagnostic biomarker for ALL in children and to examine the effect of chemotherapy on mRNA expression following the induction and after three months of receiving chemotherapy.

Methods: In this prospective study, total RNA was extracted from blood samples of 23 pediatric ALL patients on diagnosis, after one month and three months of receiving chemotherapy. Healthy pediatric volunteers ( = 12) were selected as control individuals. After cDNA synthesis, mRNA gene expression levels were quantified using quantitative real-time PCR (qRT-PCR).

Results: mRNA expression levels were significantly decreased in leukemic cells compared to their levels in cells of normal blood samples ( = 0.0001). expression levels in ALL patients after one month and three months of receiving chemotherapy decreased compared to normal blood samples ( < 0.0001 and = 0.0175 respectively). The expression level of mRNA in ALL patients after one month of chemotherapy was decreased compared to their level on diagnosis ( = 0.4413). mRNA expression levels in ALL patients after three months of chemotherapy were increased compared to their level on diagnosis ( = 0.0602). The ROC curve illustrated that mRNA expression could very efficiently discriminate ALL patients from normal counterparts (AUC=0.886, 95% CI [0.7720-1.000], SE = 0.0582, = 0.0004).

Conclusion: mRNA expression could serve as a potential diagnostic molecular biomarker for ALL in children.

References

Smith L, Glaser A, Kinsey S, Greenwood D, Chilton L, Moorman A . Long-term survival after childhood acute lymphoblastic leukaemia: population-based trends in cure and relapse by clinical characteristics. Br J Haematol. 2018; 182(6):851-858. DOI: 10.1111/bjh.15424. View

Jost F, Zierk J, Le T, Raupach T, Rauh M, Suttorp M . Model-Based Simulation of Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia. Front Physiol. 2020; 11:217. PMC: 7093595. DOI: 10.3389/fphys.2020.00217. View

Bassan R, Hoelzer D . Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011; 29(5):532-43. DOI: 10.1200/JCO.2010.30.1382. View

Pampalakis G, Diamandis E, Sotiropoulou G . The epigenetic basis for the aberrant expression of kallikreins in human cancers. Biol Chem. 2006; 387(6):795-9. DOI: 10.1515/BC.2006.100. View

Stefanini A, da Cunha B, Henrique T, Tajara E . Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes. Dis Markers. 2016; 2015:946572. PMC: 4689925. DOI: 10.1155/2015/946572. View

Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

Lejman M, Chalupnik A, Chilimoniuk Z, Dobosz M . Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children. Int J Mol Sci. 2022; 23(5). PMC: 8911213. DOI: 10.3390/ijms23052755. View

Riley L, Rupert J . Evaluation of Patients with Leukocytosis. Am Fam Physician. 2016; 92(11):1004-11. View

Moorman A . New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2016; 101(4):407-16. PMC: 5004393. DOI: 10.3324/haematol.2015.141101. View

10.

Bardelli V, Arniani S, Pierini V, Di Giacomo D, Pierini T, Gorello P . T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness. Genes (Basel). 2021; 12(8). PMC: 8394887. DOI: 10.3390/genes12081118. View

11.

Paliouras M, Borgono C, Diamandis E . Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 2007; 249(1):61-79. DOI: 10.1016/j.canlet.2006.12.018. View

12.

Teachey D, Hunger S . Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol. 2013; 162(5):606-20. DOI: 10.1111/bjh.12442. View

13.

Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V, Lianidou E . Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Ann Oncol. 2009; 20(6):1020-5. DOI: 10.1093/annonc/mdn733. View

14.

Inaba H, Mullighan C . Pediatric acute lymphoblastic leukemia. Haematologica. 2020; 105(11):2524-2539. PMC: 7604619. DOI: 10.3324/haematol.2020.247031. View

15.

Watrowski R, Cacsire Castillo-Tong D, Obermayr E, Zeillinger R . Gene Expression of Kallikreins in Breast Cancer Cell Lines. Anticancer Res. 2020; 40(5):2487-2495. DOI: 10.21873/anticanres.14219. View

16.

Yousef G, Luo L, Diamandis E . Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res. 2000; 19(4B):2843-52. View

17.

Shimura T, Ebi M, Yamada T, Yamada T, Katano T, Nojiri Y . Urinary kallikrein 10 predicts the incurability of gastric cancer. Oncotarget. 2017; 8(17):29247-29257. PMC: 5438727. DOI: 10.18632/oncotarget.16453. View

18.

Liu X, Wazer D, Watanabe K, Band V . Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 1996; 56(14):3371-9. View

19.

Dhar S, Bhargava R, Yunes M, Li B, Goyal J, Naber S . Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin Cancer Res. 2001; 7(11):3393-8. View

20.

Tailor P, Kodeboyina S, Bai S, Patel N, Sharma S, Ratnani A . Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types. Oncotarget. 2018; 9(25):17876-17888. PMC: 5915161. DOI: 10.18632/oncotarget.24947. View